You are being redirected to another site.
The MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease course will provide theoretical education and practical experience in the management of pump therapies for advanced Parkinson’s disease (Levodopa carbidopa intestinal gel and apomorphine). Additionally, the course will include innovations in the infusion therapies field e.g. Levodopa-Entacapone-Carbidopa Intestinal Gel and subcutaneous levodopa pumps. The course includes lectures on the development of the therapies, their experimental basis, effects and side effects, practical management, interactive workshops on patient selection and practical management, as well as a hands-on course on pump management.By registering for this course, you agree to the statement provided in the section below labeled 'Assumption of Risk and Liability - COVID'.
Katarzyna Smilowska, MD, PhD - Department of Neurology, Silesian Center of Neurology, Katowice, Poland
Tove Henriksen, MD - Bispebjerg Hospital, Copenhagen, DenmarkFaculty
Angelo Antonini, MD, PhD - University of Padua, Padua, Italy
Marek Balaz, MD, PhD - St. Anne's University Hospital, Brno, Czech RepublicBas Bloem, MD, PhD, FRCPE, Radboud University Medical Center, Nijmegen, Netherlands
K. Ray Chaudhuri, FRCP, DSc, FEAN - King's College, London, United Kingdom
Per Odin, MD, PhD - Lund University, Lund, Sweden
Miriam Parry - King's College Hospital NHS Trust, London, United Kingdom
Karolina Poplawska-Domaszewicz, MD, PhD - Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland
Anna Roszmann, PhD, MA, RN - Medical University of Gdansk, Gdansk, Poland
Matej Škorvánek, MD, PhD - University of P. J. Safarik, Košice, Slovakia
Upon completion of this activity, learners will be able to:
1. Describe the theoretical evidence supporting CDS-based treatment2. Define the criteria and process of selecting patients for pump therapies3. Summarize the effects of pump therapies on motor, non-motor symptoms and quality of life based on new EAN/MDS-ES Guidelines4. Demonstrate management of pump therapies including hands-on workshop on the pump management5. Identify possible side effects and complications of advanced therapies, including management of these complications
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.
Accreditation StatementThe MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease, Katowice, Poland, 02/06/2023-03/06/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease course wishes to acknowledge the following commercial supporters and exhibitors:
The MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease course has received unrestricted medical education grants from the following companies:
EVER Pharma Poland
Allie Oakley Stoffel
Courtyard Marriott Katowice City CenterUl. Uniwersytecka 13, 40-007 Katowice, PolandMeeting RoomMadagaskar 2-3
Attendee assumes all risks and accepts sole responsibility for any injury (including, but not limited to, personal injury, disability, and death), illness, damage, loss, claim, liability or expense, of any kind, that they may experience or incur in connection with attending the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease.
The International Parkinson and Movement Disorder Society’s European Section (MDS-ES) has taken preventative measures to reduce the spread of communicable disease including, but not limited to COVID-19 (“Communicable Disease”) at the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease. However, MDS cannot guarantee that attendees will not be exposed to or contract a Communicable Disease at the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease. Further, due to the nature of the facilities, services and programs offered at the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease, participants understand that attending the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease could increase their risk of contracting a Communicable Disease.
Attendee agrees to abide by all applicable COVID-19-related requirements, advisories, policies, procedures, and protocols of the hotel and MDS-ES as well as the Centers for Disease Control and Prevention (CDC), the city of Katowice, Poland, and any other governmental authority for the duration of their stay.
Attendee understands the risk that they may be exposed to or infected by a Communicable Disease by attending the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease and that such exposure or infection may result in quarantine requirements, serious illness, permanent disability and/or death. Attendee further understands that the risk of becoming exposed to or infected by a Communicable Disease at the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease may result from the actions, omissions or negligence of themselves and others, including, but not limited to, MDS-ES, its officers, employees, contractors, agents, representatives, sponsors, other participants, and any owners and lessors of premises used to conduct the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease (“Releasees”). ATTENDEE KNOWINGLY AND FREELY ASSUMES ALL SUCH RISKS, BOTH KNOWN AND UNKNOWN, EVEN IF ARISING FROM THE NEGLIGENCE OF THE RELEASEES, and assumes full responsibility for their participation in the MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease.
The MDS-ES Tailored and Innovative Pump Therapies for Parkinson’s Disease course is assessed as COMPLIANT with the MedTech Europe Code of Ethical Business Practice and EFPIA Code of Practice.This decision is available here: https://www.ethicalmedtech.eu/medtech-apps/cvs/view-event/EMT32938.
DAY 1 Lectures1.1 Advanced Parkinson's Disease Clinical Definition and New Recommendations - Tove Henriksen.pdf1.2 Multidisciplinary Team Management & Organization - Miriam Parry.pdf1.6 Apomorphine and Effects on Motor Symptoms - Karolina Poplawska-Domaszewicz.pdf1.7 Non Motor Symptoms Apomorphine in PD - K. Ray Chaudhuri.pdf1.9 LCIG and LECIG and Effects on Motor Symptoms - Katarzyna Smilowska.pdf1.10 Levodopa-Carbidopa Intestinal Gel & LECIG and Effects on Non Motor Symptoms - K. Ray Chaudhuri.pdf1.12 Innovations in the Infusion Therapies Field - Matej Skorvanek.pdfDAY 2 Lectures2.1 How to Start LCIG - Katarzyna Smilowska.pdf2.3 Management of Patients with Pump Infusion Therapies - Miriam Parry.pdf2.4 Patient Selection - Tove Henriksen.pdf2.5 Multidisciplinary Parkinson’s Disease Research - K. Ray Chaudhuri.pdf
The course evaluation and certificate of attendance are available online. To access:
23ESPUMP Final Program.pdfA copy will be available onsite.